Dr Michel Delforge speaks to ecancer about the impact of Idecabtagene Vicleucel (Ide-Cel) as compared to standard regimens on the HRQoL of patients with Triple-Class-Exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who have received at least 3–4 prior regimens including an immunomodulatory agent, a proteasome inhibitor, and daratumumab (an anti-CD38 monoclonal antibody) using data from the KarMMa-3 study.

The findings, as reported by the patients, reveal that Ide-Cel treatment significantly improves MM-relevant disease symptoms, functioning, and overall health status. The results further support the superiority of Ide-Cel over standard regimens for this patient population.

Overall, Ide-Cel treatment can help alleviate the negative impact on HRQoL in patients with multiple myeloma.